In situ suppression of dealyed-type hypersensitivity

Another mechanism for sustaining the immune privilege of the anterior chamber

J. L. Benson, J. Y. Niederkorn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Immunological rejection of a highly immunogenic, syngeneic tumour (UV5C25) in the anterior chamber (AC) of BALB/c mice was analysed. Hosts developed systemic, tumour-specific cytotoxic T lymphocyte (CTL) activity (P < 0.001) as well as systemic, tumour-specific delayed-type hypersensitivity (DTH) (P < 0.001). Histopathological featurs of tumour rejection were consistent with that of a CTL-mediated process [i.e., piecemeal necrosis of individual tumour cells by tumour-infiltrating lymphocytes (TIL)]. There was no evidence of ischaemic necrosis, perivascular cuffing, infarction, or vascular damage, as expected of a DTH-mediated process. In an effort to selectively eliminate CTL or DTH effector cells and hence alter the pattern of tumour rejection, mice were treated with anti-CD8 or anti-CD4 antibodies, respectively. Elimination of either cell population not only eliminated both systemic CTL and DTH activity to this tumour, but also resulted in progressive tumour growth . Analysis of TIL from untreated tumour-bearing hosts demonstrated tumour-specific cytolysis (P < 0.01) as well as the presence of DTH effector cells (P < 0.01). These results indicate that while both DTH and CTL effector cells are present in the AC, only the latter are active in tumour resolution in the AC; DTH effectors are active systemically, but suppressed locally. Further, these data also suggest the requirement of a CD8+ cell population for the development of a systemic DTH response to this tumour.

Original languageEnglish (US)
Pages (from-to)153-159
Number of pages7
JournalImmunology
Volume74
Issue number1
StatePublished - 1991

Fingerprint

Anterior Chamber
Hypersensitivity
Delayed Hypersensitivity
Cytotoxic T-Lymphocytes
Neoplasms
Tumor-Infiltrating Lymphocytes
Necrosis
Infarction
Population
Blood Vessels
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

In situ suppression of dealyed-type hypersensitivity : Another mechanism for sustaining the immune privilege of the anterior chamber. / Benson, J. L.; Niederkorn, J. Y.

In: Immunology, Vol. 74, No. 1, 1991, p. 153-159.

Research output: Contribution to journalArticle

@article{eca1ee413d534b798252d0dbcfd20a6c,
title = "In situ suppression of dealyed-type hypersensitivity: Another mechanism for sustaining the immune privilege of the anterior chamber",
abstract = "Immunological rejection of a highly immunogenic, syngeneic tumour (UV5C25) in the anterior chamber (AC) of BALB/c mice was analysed. Hosts developed systemic, tumour-specific cytotoxic T lymphocyte (CTL) activity (P < 0.001) as well as systemic, tumour-specific delayed-type hypersensitivity (DTH) (P < 0.001). Histopathological featurs of tumour rejection were consistent with that of a CTL-mediated process [i.e., piecemeal necrosis of individual tumour cells by tumour-infiltrating lymphocytes (TIL)]. There was no evidence of ischaemic necrosis, perivascular cuffing, infarction, or vascular damage, as expected of a DTH-mediated process. In an effort to selectively eliminate CTL or DTH effector cells and hence alter the pattern of tumour rejection, mice were treated with anti-CD8 or anti-CD4 antibodies, respectively. Elimination of either cell population not only eliminated both systemic CTL and DTH activity to this tumour, but also resulted in progressive tumour growth . Analysis of TIL from untreated tumour-bearing hosts demonstrated tumour-specific cytolysis (P < 0.01) as well as the presence of DTH effector cells (P < 0.01). These results indicate that while both DTH and CTL effector cells are present in the AC, only the latter are active in tumour resolution in the AC; DTH effectors are active systemically, but suppressed locally. Further, these data also suggest the requirement of a CD8+ cell population for the development of a systemic DTH response to this tumour.",
author = "Benson, {J. L.} and Niederkorn, {J. Y.}",
year = "1991",
language = "English (US)",
volume = "74",
pages = "153--159",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - In situ suppression of dealyed-type hypersensitivity

T2 - Another mechanism for sustaining the immune privilege of the anterior chamber

AU - Benson, J. L.

AU - Niederkorn, J. Y.

PY - 1991

Y1 - 1991

N2 - Immunological rejection of a highly immunogenic, syngeneic tumour (UV5C25) in the anterior chamber (AC) of BALB/c mice was analysed. Hosts developed systemic, tumour-specific cytotoxic T lymphocyte (CTL) activity (P < 0.001) as well as systemic, tumour-specific delayed-type hypersensitivity (DTH) (P < 0.001). Histopathological featurs of tumour rejection were consistent with that of a CTL-mediated process [i.e., piecemeal necrosis of individual tumour cells by tumour-infiltrating lymphocytes (TIL)]. There was no evidence of ischaemic necrosis, perivascular cuffing, infarction, or vascular damage, as expected of a DTH-mediated process. In an effort to selectively eliminate CTL or DTH effector cells and hence alter the pattern of tumour rejection, mice were treated with anti-CD8 or anti-CD4 antibodies, respectively. Elimination of either cell population not only eliminated both systemic CTL and DTH activity to this tumour, but also resulted in progressive tumour growth . Analysis of TIL from untreated tumour-bearing hosts demonstrated tumour-specific cytolysis (P < 0.01) as well as the presence of DTH effector cells (P < 0.01). These results indicate that while both DTH and CTL effector cells are present in the AC, only the latter are active in tumour resolution in the AC; DTH effectors are active systemically, but suppressed locally. Further, these data also suggest the requirement of a CD8+ cell population for the development of a systemic DTH response to this tumour.

AB - Immunological rejection of a highly immunogenic, syngeneic tumour (UV5C25) in the anterior chamber (AC) of BALB/c mice was analysed. Hosts developed systemic, tumour-specific cytotoxic T lymphocyte (CTL) activity (P < 0.001) as well as systemic, tumour-specific delayed-type hypersensitivity (DTH) (P < 0.001). Histopathological featurs of tumour rejection were consistent with that of a CTL-mediated process [i.e., piecemeal necrosis of individual tumour cells by tumour-infiltrating lymphocytes (TIL)]. There was no evidence of ischaemic necrosis, perivascular cuffing, infarction, or vascular damage, as expected of a DTH-mediated process. In an effort to selectively eliminate CTL or DTH effector cells and hence alter the pattern of tumour rejection, mice were treated with anti-CD8 or anti-CD4 antibodies, respectively. Elimination of either cell population not only eliminated both systemic CTL and DTH activity to this tumour, but also resulted in progressive tumour growth . Analysis of TIL from untreated tumour-bearing hosts demonstrated tumour-specific cytolysis (P < 0.01) as well as the presence of DTH effector cells (P < 0.01). These results indicate that while both DTH and CTL effector cells are present in the AC, only the latter are active in tumour resolution in the AC; DTH effectors are active systemically, but suppressed locally. Further, these data also suggest the requirement of a CD8+ cell population for the development of a systemic DTH response to this tumour.

UR - http://www.scopus.com/inward/record.url?scp=0025923830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025923830&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 153

EP - 159

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 1

ER -